AbbVie's stock fell due to decreased profitability and lowered earnings forecast. Despite surpassing revenue and EPS estimates, investors focused on declining operating margin and reduced guidance. This presents a potential buying opportunity. AbbVie has shown positive growth and investments in drug development and manufacturing.